Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Coordination and Support Action · Running

Enlighten Advancing Affordable, Immune-Based Multi-Cancer Early Detection

Coordinator
Proteotype Diagnostics Unipessoal Lda, Portugal
Runs
1 September 2026 to 30 November 2027
Status
Running
EU funding
€499k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101310234

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is the second leading cause of death in Europe, and its burden is expected to rise sharply, with the World Health Organization projecting a 77% increase in cases by 2050. Despite commitments to expand population-based screening, 50% of cancers are still detected at advanced stages and 70% of cancer deaths arise from cancers without available screening. Current multicancer detection tests, largely based on circulating tumour DNA (ctDNA), remain too insensitive for early-stage disease and too expensive for widespread use (~€875 per patient), making them unsuitable for population-scale implementation.

Enlighten®, developed by Proteotype Diagnostics, introduces a new approach to multicancer early detection (MCED), by measuring the host’s immune-driven proteomic response rather than scarce tumour-derived material. Using a simple fluorescence-based kit and an AI classifier, Enlighten® quantifies Protein Cross Sections directly from neat plasma. Independent validation shows high stage I sensitivity, with 95% overall sensitivity and 100% specificity across multiple solid tumours, at a price point compatible with decentralised, population-level screening.

The Enlighten Pre-Accelerator project will advance Enlighten® from TRL 5 to TRL 6 and BRL 4 to BRL 6 through AI model optimisation, multi-geography data harmonisation, and development of a clinician-ready digital interface. Cloud security, interoperability and SaMD documentation will be strengthened to meet IVDR and ISO 13485/IEC 62304 requirements. These activities will deliver a clinically verified, regulatory-ready platform and establish a clear pathway toward pivotal validation studies and EIC Accelerator funding.

The Enlighten Pre-Accelerator will deliver a CE-ready TRL6/BRL6 platform for affordable MCED. Enlighten® has the potential to become Europe’s first scalable MCED solution, reducing late-stage diagnoses, lowering healthcare expenditure, and enabling more equitable access to cancer prevention.

Topics

Who is involved

OrganisationCityCountryRole
Proteotype Diagnostics Unipessoal LdaTorres VedrasPortugalCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI